Psoriatic Arthritis

Circumstances that may warrant a switch in therapy to either a similar drug or a drug of a different class.

Currently available non-biologic and biologic therapies used to treat psoriatic arthritis and guidance regarding proper treatment selection and use.

Goals of therapy and considerations that need to be factored into treatment decisions for patients with psoriatic arthritis.

An overview of the clinical manifestations of psoriatic arthritis and recommendations for properly assessing patient symptoms when measuring disease severity.

Strategies that can help clinicians assess patients with psoriatic arthritis for signs of disease progression.

The impact of psoriatic arthritis on patients’ quality of life and importance of an early, accurate diagnosis.

Patients with psoriatic arthritis (PsA) treated with guselkumab resulted in higher percentages of resolved enthesitis by Week 24 and maintained those results through 1 year when compared with a placebo.

While incidence rates remained stable throughout the study period, incidence rates in females increased 3% per year between 2000 and 2017. The increase was seen primarily in women 40-49 and 50-59.

A study finds low risk of malignancy from secukinumab treatment for psoriasis, psoriatic arthritis and ankylosing spondylitis patients, despite limited data.

A recent study finds increasing number of women with PsA, but an overall stable incidence of disease compared to previous studies in same population.

Mortality rates were similar in COVID-19 patients with and without chronic inflammatory diseases.

Guselkumab is the first and only approved IL-23 inhibitor therapy used to treat adults with active PsA and moderate to severe plaque psoriasis (PsO). The medication showed efficacy in skin clearance and joint symptom relief and passed safety measures. Additionally, physical function, health-related quality of life, and resolution of enthesitis and dactylitis were confirmed through week 100.

The diagnosis of psoriatic arthritis (PsA) may be delayed by more than 2 years in half of patients, especially those of younger age at symptom onset, or with a higher body mass index (BMI) or enthesitis before diagnosis.

A majority of patients with active psoriatic arthritis achieved and maintained skin clearance, joint symptom relief through year 2 of treatment.

In patients with psoriatic arthritis refractory or intolerant to biologic disease-modifying antirheumatic drugs (DMARDs), upadacitinib (Abbvie; Rinvoq) 15 mg and 30 mg once per day was more effective than placebo over 24 weeks in improving signs and symptoms of psoriatic arthritis.

Generally, guidelines recommend beginning psoriatic arthritis (PsA) treatment with tumor necrosis factor inhibitors (TNFis). However, not all patients respond to this method. Ixekizumab (IXE) improved the signs and symptoms of PsA in patients who had exhibited inadequate response to 1 or 2 TNFis.

The drug is commonly used to treat diseases such as psoriatic arthritis, Behcet’s Syndrome, and plaque psoriasis.

Apremilast has been prescribed to more than 250,000 patients with plaque psoriasis or psoriatic arthritis since it was approved in 2014.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 12, 2021.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending February 5, 2021.

In this 48-week, phase 3, randomized controlled trial, investigators examined patient-reported outcomes of patients with psoriatic arthritis receiving methotrexate monotherapy, etanercept monotherapy, or a combination of both drugs.

Investigators determined, “Treatment with TNF inhibitors is not associated with increased risks of solid cancer overall, or eight common cancer types. There were no indications of different crude incidence of solid cancers overall by TNF inhibitor agent.”